CU23009A1 - PREPARATIONS TO POWER THE IMMUNOGENICITY OF PREPARATIONS TO POWER THE IMMUNOGENICITY OF ANTIGENS LITTLE IMMUNOGENIC ANTIGENS LITTLE IMMUNOGENIC - Google Patents

PREPARATIONS TO POWER THE IMMUNOGENICITY OF PREPARATIONS TO POWER THE IMMUNOGENICITY OF ANTIGENS LITTLE IMMUNOGENIC ANTIGENS LITTLE IMMUNOGENIC

Info

Publication number
CU23009A1
CU23009A1 CU20010167A CU20010167A CU23009A1 CU 23009 A1 CU23009 A1 CU 23009A1 CU 20010167 A CU20010167 A CU 20010167A CU 20010167 A CU20010167 A CU 20010167A CU 23009 A1 CU23009 A1 CU 23009A1
Authority
CU
Cuba
Prior art keywords
compositions
antigens
immunogenic
vaccine
lysates
Prior art date
Application number
CU20010167A
Other languages
Spanish (es)
Inventor
Ramirez Belinda Sanchez Ramirez Belinda Sanchez
Delgado Joel De Leon Delgado Joel De Leon
Pestana Eduardo Raul Suarez Pestana Eduardo Suarez
Rodriguez Rolando Perez Rodriguez Rolando Perez
Rodriguez Yildian Diaz Rodriguez Yildian Diaz
Acosta Anabel Alvarez Acosta Anabel Alvarez
Molina Luis Enrique Fernandez Molina Lui Fernandez
Pardillo Circe Mesa Pardillo Circe Mesa
Original Assignee
Ct De Inmunologia Molecular Ct De Inmunologia Mole
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Inmunologia Molecular Ct De Inmunologia Mole filed Critical Ct De Inmunologia Molecular Ct De Inmunologia Mole
Priority to CU20010167A priority Critical patent/CU23009A1/en
Priority to PE2001001202A priority patent/PE20020572A1/en
Priority to ARP010105662A priority patent/AR031638A1/en
Priority to MXPA03005032A priority patent/MXPA03005032A/en
Priority to KR1020037007634A priority patent/KR100850473B1/en
Priority to JP2002547529A priority patent/JP4210519B2/en
Priority to EP01999387A priority patent/EP1356822B1/en
Priority to EA200300640A priority patent/EA005138B1/en
Priority to CA2431188A priority patent/CA2431188C/en
Priority to CNB018215602A priority patent/CN1291755C/en
Priority to AU2002221519A priority patent/AU2002221519B2/en
Priority to US10/003,463 priority patent/US7776342B2/en
Priority to PCT/CU2001/000010 priority patent/WO2002045746A2/en
Priority to DE60143363T priority patent/DE60143363D1/en
Priority to DK01999387.2T priority patent/DK1356822T3/en
Priority to BR0116013-3 priority patent/BRPI0116013B8/en
Priority to UY27059A priority patent/UY27059A1/en
Priority to AT01999387T priority patent/ATE485833T1/en
Priority to AU2151902A priority patent/AU2151902A/en
Priority to NZ526282A priority patent/NZ526282A/en
Priority to ZA200304411A priority patent/ZA200304411B/en
Priority to HK04106497A priority patent/HK1063726A1/en
Publication of CU23009A1 publication Critical patent/CU23009A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con los medios La presente invención se relaciona con los medios para hacer inmunogénicos péptidos, polipéptidos, ppara hacer inmunogénicos péptidos, polipéptidos, proteínas, sus correspondientes secuencias de ácidoroteínas, sus correspondientes secuencias de ácidos nucleicos, células blanco de interés vacunal y ss nucleicos, células blanco de interés vacunal y sus lisados, sin hacer cambios estructurales en dicus lisados, sin hacer cambios estructurales en dichos antígenos, mediante su asociación con proteolihos antígenos, mediante su asociación con proteoliposomas de muy pequena talla. El objeto de esta inposomas de muy pequena talla. El objeto de esta invención es proporcionar composiciones inmunogénicavención es proporcionar composiciones inmunogénicas que contienen péptidos, polipéptidos, proteínas,s que contienen péptidos, polipéptidos, proteínas, sus correspondientes secuencias de ADN, células o sus correspondientes secuencias de ADN, células o sus lisados y proteoliposomas de muy pequena tall sus lisados y proteoliposomas de muy pequena talla (VSSP), formados estos últimos al unir el complea (VSSP), formados estos últimos al unir el complejo de proteínas de la membrana externa (CPME) de Njo de proteínas de la membrana externa (CPME) de Neisseria meningitidis con gangliósidos, mediante eeisseria meningitidis con gangliósidos, mediante enlaces hidrófobos. Adicionalmente se describe cómonlaces hidrófobos. Adicionalmente se describe cómo estas composiciones pueden formularse solas o for estas composiciones pueden formularse solas o formando emulsiones con el adyuvante incompleto de Frmando emulsiones con el adyuvante incompleto de Freud (AIF) y también ser liofilizadas. La esencia deud (AIF) y también ser liofilizadas. La esencia de la invención consiste en describrir composicionee la invención consiste en describrir composiciones que permiten hacer inmunogénicos antígenos de mus que permiten hacer inmunogénicos antígenos de muy baja inmunogenicidad, tales como receptores de fy baja inmunogenicidad, tales como receptores de factores de crecimiento, sin necesidad de recurrir actores de crecimiento, sin necesidad de recurrir a cambios estructurales en los mismos. En particula cambios estructurales en los mismos. En particular esta invención muestra cómo preparar composicioar esta invención muestra cómo preparar composiciones inmunoestimuladoras capaces de generar respuesnes inmunoestimuladoras capaces de generar respuestas inmunes antígeno-específicas incluso en huéspetas inmunes antígeno-específicas incluso en huéspedes inmunocomprometidos, como son los que padecen des inmunocomprometidos, como son los que padecen de cáncer e infecciones de origen viral o bacteriade cáncer e infecciones de origen viral o bacterianas crónicas. En estos pacientes, la administraciónas crónicas. En estos pacientes, la administración de las composiciones vacunales descritas en estan de las composiciones vacunales descritas en esta invención permite restaurar la funcionalidad de s invención permite restaurar la funcionalidad de sectores de su sistema inmunitario. Las composicionectores de su sistema inmunitario. Las composiciones vacunales de esta invención pueden ser utilizades vacunales de esta invención pueden ser utilizadas para proteger de o tratar enfermedades infeccioas para proteger de o tratar enfermedades infecciosas, malignas o autoinmunes. sas, malignas o autoinmunes.The present invention relates to the means The present invention relates to the means for making immunogenic peptides, polypeptides, for making immunogenic peptides, polypeptides, proteins, their corresponding acido-protein sequences, their corresponding nucleic acid sequences, white cells of vaccine interest and nucleic ss, white cells of vaccine interest and their lysates, without making structural changes in lysed lysates, without making structural changes in said antigens, through their association with proteolytic antigens, through their association with very small proteoliposomes. The object of this very small size inposomes. The object of this invention is to provide immunogenic compositions is to provide immunogenic compositions containing peptides, polypeptides, proteins, s containing peptides, polypeptides, proteins, their corresponding DNA sequences, cells or their corresponding DNA sequences, cells or their lysates and proteoliposomes. of very small tall its lysates and proteoliposomes of very small size (VSSP), the latter formed by joining the complea (VSSP), formed the latter by joining the outer membrane protein complex (CPME) of Njo membrane proteins external (CPME) of Neisseria meningitidis with gangliosides, using eeisseria meningitidis with gangliosides, through hydrophobic bonds. Additionally, hydrophobic couplings are described. Additionally, it is described how these compositions can be formulated alone or for these compositions can be formulated alone or forming emulsions with the incomplete adjuvant of Frmando emulsions with the incomplete adjuvant of Freud (AIF) and also be lyophilized. The essence of debts (IDA) and also be lyophilized. The essence of the invention consists in describing the composition of the invention consists in describing compositions that allow to make immunogenic antigens of mus that allow to make immunogenic antigens of very low immunogenicity, such as f and low immunogenicity receptors, such as growth factor receptors, without need of resorting to growth actors, without resorting to structural changes in them. In particular structural changes in them. In particular, this invention shows how to prepare composing this invention shows how to prepare immunostimulatory compositions capable of generating immunostimulatory responses capable of generating antigen-specific immune responses even in antigen-specific immune hosts even in immunocompromised hosts, such as those suffering from immunocompromised hosts, such as those who suffer from cancer and infections of viral origin or cancer bacteria and infections of viral or chronic bacterial origin. In these patients, the chronic administration. In these patients, the administration of the vaccine compositions described in these of the vaccine compositions described in this invention makes it possible to restore the functionality of the invention allows to restore the functionality of sectors of your immune system. The composers of your immune system. The vaccine compositions of this invention may be vaccine uses of this invention may be used to protect from or treat infectious diseases to protect from or treat infectious, malignant or autoimmune diseases. sas, malignant or autoimmune.

CU20010167A 2000-12-06 2001-07-12 PREPARATIONS TO POWER THE IMMUNOGENICITY OF PREPARATIONS TO POWER THE IMMUNOGENICITY OF ANTIGENS LITTLE IMMUNOGENIC ANTIGENS LITTLE IMMUNOGENIC CU23009A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
CU20010167A CU23009A1 (en) 2001-07-12 2001-07-12 PREPARATIONS TO POWER THE IMMUNOGENICITY OF PREPARATIONS TO POWER THE IMMUNOGENICITY OF ANTIGENS LITTLE IMMUNOGENIC ANTIGENS LITTLE IMMUNOGENIC
PE2001001202A PE20020572A1 (en) 2000-12-06 2001-11-29 PREPARATIONS TO ENHANCE THE IMMUNOGENICITY OF UNIMMUNOGENIC ANTIGENS
ARP010105662A AR031638A1 (en) 2000-12-06 2001-12-05 PHARMACEUTICAL COMPOSITIONS TO POWER THE IMMUNOGENICITY OF LITTLE IMMUNOGENIC ANTIGENS
MXPA03005032A MXPA03005032A (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens.
KR1020037007634A KR100850473B1 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
JP2002547529A JP4210519B2 (en) 2000-12-06 2001-12-06 Pharmaceutical composition for enhancing the immunogenicity of a low immunogenic antigen
EP01999387A EP1356822B1 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
EA200300640A EA005138B1 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
CA2431188A CA2431188C (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
CNB018215602A CN1291755C (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU2002221519A AU2002221519B2 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
US10/003,463 US7776342B2 (en) 2000-12-06 2001-12-06 Preparations that potentiate immunogenicity in low immunogenic antigens
PCT/CU2001/000010 WO2002045746A2 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
DE60143363T DE60143363D1 (en) 2000-12-06 2001-12-06 PHARMACEUTICAL COMPOSITIONS THAT PROMOTE THE IMMUNOGENICITY OF WEAK IMMUNOGENIC ANTIGENES
DK01999387.2T DK1356822T3 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions that enhance the immunogenicity of weakly immunogenic antigens
BR0116013-3 BRPI0116013B8 (en) 2000-12-06 2001-12-06 pharmaceutical composition to enhance the immunogenicity of poorly immunogenic antigens, and use of pharmaceutical composition
UY27059A UY27059A1 (en) 2000-12-06 2001-12-06 PREPARATIONS TO POWER THE IMMUNOGENCITY OF LITTLE IMMUNOGENIC ANTIGENS
AT01999387T ATE485833T1 (en) 2000-12-06 2001-12-06 PHARMACEUTICAL COMPOSITIONS THAT PROMOTE THE IMMUNOGENICITY OF WEAKLY IMMUNOGENIC ANTIGENS
AU2151902A AU2151902A (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
NZ526282A NZ526282A (en) 2000-12-06 2003-06-04 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
ZA200304411A ZA200304411B (en) 2000-12-06 2003-06-05 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens.
HK04106497A HK1063726A1 (en) 2000-12-06 2004-08-30 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20010167A CU23009A1 (en) 2001-07-12 2001-07-12 PREPARATIONS TO POWER THE IMMUNOGENICITY OF PREPARATIONS TO POWER THE IMMUNOGENICITY OF ANTIGENS LITTLE IMMUNOGENIC ANTIGENS LITTLE IMMUNOGENIC

Publications (1)

Publication Number Publication Date
CU23009A1 true CU23009A1 (en) 2004-12-17

Family

ID=46639758

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20010167A CU23009A1 (en) 2000-12-06 2001-07-12 PREPARATIONS TO POWER THE IMMUNOGENICITY OF PREPARATIONS TO POWER THE IMMUNOGENICITY OF ANTIGENS LITTLE IMMUNOGENIC ANTIGENS LITTLE IMMUNOGENIC

Country Status (1)

Country Link
CU (1) CU23009A1 (en)

Similar Documents

Publication Publication Date Title
AR031638A1 (en) PHARMACEUTICAL COMPOSITIONS TO POWER THE IMMUNOGENICITY OF LITTLE IMMUNOGENIC ANTIGENS
CN102203252B (en) Immunologic adjuvant compound based on flagellin and application thereof
CN105307673A (en) Subunit vaccine delivery platform for robust humoral and cellular immune responses
Kar et al. Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice
SE8205892D0 (en) IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
Alexyuk et al. Adjuvant activity of multimolecular complexes based on Glycyrrhiza glabra saponins, lipids, and influenza virus glycoproteins
BR112013012555B8 (en) ISOLATED IMMUNOGENIC PEPTIDE DERIVED FROM AN ANTIGEN PROTEIN, ITS USES, METHOD FOR THE PREPARATION OF A PEPTIDE WITH THE CAPACITY OF PROVOKING THE ACTIVATION OF NKT CELLS AND IN VITRO METHOD FOR OBTAINING A SPECIFIC ANTIGEN CD4+ NKT CELL POPULATION
EP0841941A4 (en) Novel non-pyrogenic bacterial strains and use of the same
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
PT900380E (en) METHODS FOR SELECTING AND PRODUCING PEPTIDIC EPITHOPES OF T-CELLS AND VACCINES INCORPORATING THE REFERRED EPITHOPES SELECTED
TW200510538A (en) Functionally reconstituted viral membranes containing adjuvant
DK2054431T3 (en) Conformers of bacterial adhesins
ATE389397T1 (en) ADJUVANT COMPOSITIONS
Stuart et al. Cassette-based presentation of SIV epitopes with recombinant gas vesicles from halophilic archaea
Adamiak et al. Archaeosomes and gas vesicles as tools for vaccine development
Chiang et al. Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice
Defaus et al. Designing functionally versatile, highly immunogenic peptide-based multiepitopic vaccines against foot-and-mouth disease virus
Labrada et al. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy
Chen et al. Peptide-Based Therapeutic HPV Cancer Vaccine Synthesized via Bacterial Outer Membrane Vesicles
Karpenko et al. Results of phase I clinical trials of a combined vaccine against HIV-1 based on synthetic polyepitope immunogens
CU23009A1 (en) PREPARATIONS TO POWER THE IMMUNOGENICITY OF PREPARATIONS TO POWER THE IMMUNOGENICITY OF ANTIGENS LITTLE IMMUNOGENIC ANTIGENS LITTLE IMMUNOGENIC
BR112015013625A2 (en) vaccination adjuvant, preparation and vaccines containing the same
Palitzsch et al. Mucin Glycopeptide‐Protein Conjugates–Promising Antitumor Vaccine Candidates
AR042237A1 (en) OBTAINING COCLEAR STRUCTURES, VACCINE COMPOSITIONS, ASSISTANTS AND THEIR INTERMEDIARIES
CN106581667B (en) Design, preparation method and application of echinococcus multilocularis subunit vaccine LTB-Emy162